Discover
FENC
Fennec Pharmaceuticals Inc.
10.34
2 x 7.60
2 x 13.17
bid
ask
-
0.41
3.81%
2 @ 04:00 PM
10.34 +0.00 (0.00%)
| Ytd | 34.29% | |
| 1y | 24.58% |
10.21
day range
10.83
5.65
52 week range
11.31
| Open | 10.71 | Prev Close | 10.75 | Low | 10.21 | High | 10.83 | Mkt Cap | 359.18M |
| Vol | 267.58K | Avg Vol | 273.27K | EPS | -0.29 | P/E | N/A | Forward P/E | 16.78 |
| Beta | 0.27 | Short Ratio | 13.06 | Inst. Own | 54.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 8.67 | 200-d Avg | 8.09 | 1yr Est | 13.60 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.13 | -0.21 | -0.08 | -61.54% |
| 2024-08-13 | 2024-06 | 0.06 | -0.2 | -0.26 | -433.33% |
| 2024-05-14 | 2024-03 | 0.49 | 0.41 | -0.08 | -16.33% |
| 2024-03-21 | 2023-12 | 0.02 | -0.1 | -0.12 | -600.00% |
| 2023-11-06 | 2023-09 | -0.11 | -0.07 | 0.04 | 36.36% |
| 2023-08-03 | 2023-06 | -0.18 | -0.21 | -0.03 | -16.67% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-17 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-14 | Craig-Hallum | Upgrade | Buy | Buy |
| 2024-05-15 | Craig-Hallum | Upgrade | Buy | Buy |
| 2024-05-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-04-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-12-01 | ANDRADE ROBERT C | Chief Financial Officer | 128.42K | Stock Award(Grant) |
| 2024-04-21 | HAIGH ADRIAN J | Chief Operating Officer | 0.00 | Conversion of Exercise of derivative security |
| 2023-11-15 | ISLAM KHALID | Director | 213.83K | Conversion of Exercise of derivative security |
| 2024-12-01 | RALLIS CHRISTOPHER ANIGERON | Director | 52.21K | Conversion of Exercise of derivative security |
| 2024-12-04 | RAYKOV ROSTISLAV CHRISTOV | Director | 66.43K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Southpoint Capital Advisors Lp | 4.08M | 25.32M | 14.84% |
| 2024-09-29 | Sonic Gp LLC | 2.41M | 14.95M | 8.76% |
| 2024-09-29 | Solas Capital Management, LLC | 1.92M | 11.95M | 7.00% |
| 2024-09-29 | DG Capital Management, LLC | 1.52M | 9.45M | 5.54% |
| 2024-09-29 | Blackrock Inc. | 1.23M | 7.64M | 4.48% |
| 2024-09-29 | Vanguard Group Inc | 1.05M | 6.51M | 3.81% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 876.21K | 5.44M | 3.19% |
| 2024-10-30 | iShares Russell 2000 ETF | 559.37K | 3.47M | 2.04% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 241.02K | 1.50M | 0.88% |
| 2024-10-30 | iShares Russell 2000 Value ETF | 165.51K | 1.03M | 0.60% |
| 2024-08-30 | Vanguard Russell 2000 Index Fund | 94.58K | 587.34K | 0.34% |
| 2024-07-30 | Schwab Capital Trust-Small Cap Index Fund | 55.45K | 344.36K | 0.20% |
Split
| Split | Date |
|---|---|
| 0.05556 : 1 | 2011-08-30 |
| 0.2 : 1 | 2005-08-02 |